Dachaigh › Leukemia myeloid geur › Kansas
Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Kansas
Tha 21 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann an Kansas.
Bailtean ann an Kansas
Teacsa sgrùdaidh oifigeil (Beurla)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- agus 7 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05564390Ivosidenib as Post-HSCT Maintenance for AML
- Kansas University Medical Center, Kansas City
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06707493Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- agus 4 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- agus 1 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- agus 1 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- agus 2 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06317649Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Kansas City KS-KUMC, Fairway
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Kansas City KS-KUMC, Kansas City
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- agus 1 a bharrachd
A’ fastadhÌre 1
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Kansas Cancer Center, Kansas City
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Kansas Cancer Center, Westwood
A’ fastadhÌre 3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 17 Iuch 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Kansas, Westwood
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- University of Kansas Medical Center Research Institute, Inc., Kansas City
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gibl 2026 · NCT06146257Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
A’ fastadhÌre 1
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 25 Màrt 2026 · NCT03533816A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
A’ fastadhÌre 2
Aoisean 18 gu 66 · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- The University of Kansas Medical Center Research Institute, Fairway
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- KU Cancer Center, Kansas City
A’ fastadhÌre 1
Aoisean 65 agus nas sine · Gach gnè · Air ùrachadh 16 Dùbh 2025 · NCT06552416APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- University of Kansas, Fairway
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Cèit 2025 · NCT06634394Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- University of Kansas Cancer Center, Fairway
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Màrt 2025 · NCT02781883Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- University of Kansas Cancer Center, Fairway
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Ògmh 2020 · NCT04167696Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.